The controversy surrounding Covid-19’s origin continues to heat up, as the National Institutes of Health’s recent removal of genetic data about the novel coronavirus virus from the NIH archive was brought into the spotlight.
If you are not happy with the results below please do another search
50 search results for:
Emergent BioSolutions signed a five-year agreement with Providence Therapeutics to develop and manufacture the Canadian biotechnology company’s Covid-19 vaccine candidate for about $90 million.
CureVac said on Sept. 14 the German biotech firm cancelled contract manufacturing deals for the company’s experimental Covid-19 vaccine with two prospective partners, after rivals with approved shots boosted production.
Johnson & Johnson said the company’s Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.
Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.
Although it’s difficult, when faced with a cancer diagnosis, it’s important to find the best health care facility to receive treatment. Improving the future of cancer tech, this posting looks at some of the most high-tech cancer hospitals in America.
Syneos Health company AnswerSuite revealed data showing the industry’s increased comfort with remote detailing, indicating that the hybrid platform strategy of both in-person and remote detailing interactions has become established.
A study published in the BMJ suggests that about one-third of cancer indications receiving approval under an Accelerated Approval pathway are still on product labels even after follow-up studies did not confirm their benefits.
Additional Covid-19 vaccine booster shots are not needed for the general population, leading scientists including two departing senior U.S. Food and Drug Administration officials and several from the World Health Organization (WHO) said in an article published in a medical journal on Sept. 13.
Drugmaker Merck & Co. Inc. sees potential U.S. emergency use authorization for the company’s experimental Covid-19 antiviral treatment, molnupiravir, before year-end 2021.